SAN JOSE, Calif., Jan. 21, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...
China NMPA grants marketing authorization to IMPACT Therapeutics’ Senaparib for 1L maintenance therapy in ovarian cancer: Shanghai Saturday, January 18, 2025, 15:30 Hrs [IST] IM ...